乳腺癌前哨淋巴结阳性后腋窝放疗或手术:随机对照EORTC 10981-22023 AMAROS试验10年结果
AMAROS试验纳入cT1-2、临床淋巴结阴性但前哨淋巴结阳性的乳腺癌患者,随机接受腋窝淋巴结清扫(ALND,n=744)或腋窝放疗(ART,n=681)。10年分析显示两组腋窝复发率均低且无统计学差异,总生存和无病生存无差异,ART组淋巴水肿发生率显著更低;作者认为应考虑ART。
要点
- 10年腋窝复发累积发生率ALND组0.93% vs ART组1.82%(HR 1.71,95%CI 0.67-4.39)。
- 总生存(HR 1.17,95%CI 0.89-1.52)与无病生存(HR 1.19,95%CI 0.97-1.46)无差异。
- 更新5年分析淋巴水肿率ALND组24.5% vs ART组11.9%(P<.001)。
核心结论
- 10年分析证实ART和ALND后腋窝复发率均低,总生存、无病生存和局部区域控制无差异。
- 考虑到手臂并发症更少,对于前哨淋巴结阳性的cT1-2乳腺癌患者,ART优于ALND。
研究设计与样本
- 开放标签、多中心III期非劣效性随机对照试验(EORTC 10981-22023 AMAROS)。
- 4,806例患者接受前哨淋巴结活检,其中1,425例淋巴结阳性并随机分配至ALND组(n=744)或ART组(n=681)。
主要发现
- 意向性治疗分析:10年腋窝复发累积发生率ALND组0.93%(95%CI 0.18-1.68;7例事件)vs ART组1.82%(95%CI 0.74-2.94;11例事件),HR 1.71(95%CI 0.67-4.39)。
- 总生存HR 1.17(95%CI 0.89-1.52),无病生存HR 1.19(95%CI 0.97-1.46),均无差异。
- 更新5年分析:ALND组淋巴水肿率24.5% vs ART组11.9%(P<.001)。
- 5年内生活质量量表评分未显示治疗间差异。
- 探索性分析:10年第二原发癌累积发生率ART组12.1%(95%CI 9.6-14.9)vs ALND组8.3%(95%CI 6.3-10.7)。
临床怎么用
- 作者认为,对于前哨淋巴结阳性的cT1-2乳腺癌患者,考虑到手臂并发症更少,ART优于ALND。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The European Organisation for Research and Treatment of Cancer 10981-22023 AMAROS trial evaluated axillary lymph node dissection (ALND) versus axillary radiotherapy (ART) in patients with cT1-2, node-negative breast cancer and a positive sentinel node (SN) biopsy. At 5 years, both modalities showed excellent and comparable axillary control, with significantly less morbidity after ART. We now report the preplanned 10-year analysis of the axillary recurrence rate (ARR), overall survival (OS), and disease-free survival (DFS), and an updated 5-year analysis of morbidity and quality of life. METHODS: In this open-label multicenter phase III noninferiority trial, 4,806 patients underwent SN biopsy; 1,425 were node-positive and randomly assigned to either ALND (n = 744) or ART (n = 681). RESULTS: Per intention-to-treat analysis, 10-year ARR cumulative incidence was 0.93% (95% CI, 0.18 to 1.68; seven events) after ALND and 1.82% (95% CI, 0.74 to 2.94; 11 events) after ART (hazard ratio [HR], 1.71; 95% CI, 0.67 to 4.39). There were no differences in OS (HR, 1.17; 95% CI, 0.89 to 1.52) or DFS (HR, 1.19; 95% CI, 0.97 to 1.46). ALND was associated with a higher lymphedema rate in updated 5-year analyses (24.5% v 11.9%; P < .001). Quality-of-life scales did not differ by treatment through 5 years. Exploratory analysis showed a 10-year cumulative incidence of second primary cancers of 12.1% (95% CI, 9.6 to 14.9) after ART and 8.3% (95% CI, 6.3 to 10.7) after ALND. CONCLUSION: This 10-year analysis confirms a low ARR after both ART and ALND with no difference in OS, DFS, and locoregional control. Considering less arm morbidity, ART is preferred over ALND for patients with SN-positive cT1-2 breast cancer.
引用
- Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2022. PMID: 36383926. doi:10.1200/JCO.22.01565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。